VPC-14449
VPC-14449 is a potent and selective inhibitor of the DNA-binding domain of the androgen receptor (AR-DBD), with IC50 of 0.34 μM for full-length human AR. VPC-14449 reduces the ability of full-length AR as well as AR variants to interact with chromatin. VPC-14449 can be used for the research of prostate cancer[1][2].
Product Specifications
CAS Number
1621375-32-3
UNSPSC
12352005
Target
Androgen Receptor
Type
Reference compound
Related Pathways
Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/vpc-14449.html
Concentration
10mM
Purity
99.51
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
BrC1=CN(C2=CSC(N3CCOCC3)=N2)C(Br)=N1
Molecular Formula
C10H10Br2N4OS
Molecular Weight
394.09
References & Citations
[1]Dalal K, et, al. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. J Biol Chem. 2014 Sep 19;289 (38) :26417-26429.|[2]Dalal K, et, al. Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions. Mol Cancer Ther. 2017 Oct;16 (10) :2281-2291.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
036750-AP 200 µL
HPS5, NT (HPS5, AIBP63, KIAA1017, Hermansky-Pudlak syndrome 5 protein, Alpha-integrin-binding protein 63, Ruby-eye protein 2 homolog) (AP) discontinued
Sign In for Pricing
View Details 